HK Stock Market Move | GENFLEET-B(02595) increases by more than 5%, intending to repurchase H shares not exceeding 350 million Hong Kong dollars. RAS targeting matrix and differentiation layout in the field of cancer continue to advance.

GENFLEET-B(02595) rose more than 5% in the morning, as of the time of writing, it has risen by 4.12%, to 28.3 HK dollars, with a turnover of 186.748 million HK dollars. In terms of news, GENFLEET-B issued an announcement on June 29, 2026, that the Board of Directors formally decided to exercise the authorization to repurchase shares, intending to repurchase H shares (share repurchase) in the open market from time to time, with a maximum amount not exceeding 350 million HK dollars, and the share repurchase period will expire when the authorization to repurchase shares expires. The company will conduct the share repurchase in compliance with the Listing Rules of the Hong Kong Stock Exchange. China Securities Co., Ltd. previously released a research report stating that two research results, GFH375 and GFS202A of Jin Fang Pharma, were selected for the 2026 ASCO Annual Meeting. Among them, GFH375 showed preliminary efficacy and manageable safety in patients with KRAS G12D mutation in CCA and CRC; GFS202A Phase I preliminary data support the feasibility of dual targeting of GDF15/IL-6 to improve tumor cachexia. The company's differentiated layout in RAS targeting matrix and cachexia continues to progress.